Bluejay Diagnostics (BJDX) has issued an announcement.
Bluejay Diagnostics, Inc. has ended its agreement with DLA, LLC, leading to the departure of Interim CFO Frances Scally. The company’s CEO, Neil Dey, will take over as the principal financial and accounting officer. Additionally, Bluejay announced that its 2024 annual stockholders’ meeting is scheduled for May 14, with April 3 set as the record date for stockholder voting eligibility.
Learn more about BJDX stock on TipRanks’ Stock Analysis page.
